In another review of 356 GCs from the TCGA database, it was found that TP53MUT tumors had lower levels of anti-tumor immunity and a decreased response to immune checkpoint inhibitor therapy as compared to TP53WT tumors.35 On the other hand, sub-group analysis of the phase III GOLD trial investigating olaparib and paclitaxel combination therapy in recurrent and metastatic GC found no difference in therapeutic response based on TP53 mutation status.36 More studies are needed to assess the predictive ability of TP53 mutation in isolation and in conjunction with other molecular alterations. Here, TP53 is linked to gastric cancer.